Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Completed · Phase 1

Conditions studied: Healthy, Renal Dysfunction

In brief

This was an open-label, nonrandomized, multi-center, single-dose, parallel group study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan (ACH-0144471) compared to demographically-matched healthy participants with normal renal function.

Key facts

Study ID

NCT04935294

Run by

Alexion Pharmaceuticals, Inc.

People needed

16

Starts

2018-01-24

Expected to finish

2018-05-29

Last updated by the study team

2021-06-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Where it is running

• Clinical Trial Site — Miami, Florida, United States
• Clinical Trial Site — Orlando, Florida, United States
• Clinical Trial Site — Minneapolis, Minnesota, United States
• Clinical Trial Site — Saint Paul, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.